



The 28th Annual Meeting

of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis

14-15.11.24
 DAN HOTEL TEL AVIV

SCIENTIFIC PROGRAM

Thursday 14/11/2024

08:00-08:45	Registration
08:45-09:00	Welcome
09:00-11:05	Session 1: Basic science
Chairpersons	Andrea Szuchman Sapir & Dov Gavish
09:00-09:15	Untargeted metabolomics reveals biomarkers for the diagnosis of coronary artery plaques as observed by coronary cardiac computed tomography <i>Soliman Khatib</i> , Department of Nutrition and Natural Products, Migal, Tel-Hai.
09:20-09:35	The Fluid Mechanics of Vascular Diseases and Localized Therapeutics <i>Netanel Korin</i> , Department of Biomedical Engineering, Technion.
09:40-09:55	Gene deletion of FAT10 modulates hepatic lipid metabolism during fasting and diet-induced de-novo lipogenesis in mice <i>Yehuda Kamari</i> , The Bert W. Strassburger Lipid Center, Sackler Faculty of Medicine, Tel-Aviv University.
10:00-10:30	Research award presentation (10 minutes each) <i>Moran Yadid</i> , The Azrieli Faculty of Medicine, Bar-Ilan University, Safed. <i>Nethanel Zacks</i> , Department of Cardiology, Shaare-Zedek Medical Center. <i>Nitai Alter</i> , department of cardiology, Kaplan medical center.
10:35-11:05	<u>Key Note</u>: A new SPRING in cholesterol metabolism: new functional and structural insight <i>Noam Zelcer</i> , Department of Medical Biochemistry Academic Medical Center of the University of Amsterdam, The Netherlands.
11:05-11:40	Coffee break
11:40-13:50	Session 2: Cardiovascular genetics
Chairpersons	Donna Zwas & Alexandros Tselepis
11:40-11:55	The Genetic link between Depression and Cardiovascular Disease in Premenopausal Women <i>Arnon Bloom</i> , Department of Medicine, Laniado Hospital.

12:00-12:20	Debate: should we be sending heterozygous FH patients for genetic testing for: Ronen Durst Against: TBD
12:25-13:15	Cases in Cardiovascular genetics (10 minutes for each case) a. case of sitosterolemia b. Family with progeria c. autosomal recessive combined lipase deficiency d. apo-b e. apo-a
13:20-13:50	<u>Key note:</u> The PCSK9 content in platelets of HeFH patients. Role in platelet functionality and the effect of anti-PCSK9 mAbs <i>Alexandros Tselepis</i> , Emeritus Professor of Clinical Biochemistry, Atherothrombosis Research Centre / Department of Chemistry, University of Ioannina, Greece
13:50- 15:00	Lunch
15:00-15:15	Sustained LDL-C reduction in ASCVD, from long-term trials to real world implementation <i>Dov Gavish</i> , Shaare Zedek Medical Center, Israel sponsored by Novartis
15:20-17:05	Session 3: Non-conventional drivers and protectors of atherosclerosis
Chairpersons	Yehuda Kamari & Ed Fisher
15:20- 15:15	Dynamic life style-induced changes in Asymmetric Dimethylarginine (ADMA) correlate with alteration in lipid profile and fasting insulin in subjects with the metabolic syndrome <i>Bruria Tal</i> , The Sagol Center for the Metabolic Syndrome, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center
15:20-15:50	<u>Key note:</u> Regression of atherosclerosis: many approaches to achieve the same goal <i>Ed Fisher</i> , Leon H. Charney Professor of Cardiovascular Medicine, Director, Marc and Ruti Bell Vascular Biology Program, Director of Translational Research, The Center for the Prevention of Cardiovascular Disease Member, Cardiovascular Research Center
15:55-16:10	The residual risk of ASCVD patient - what else can be done? <i>Shlomi Matetzky</i> . Director Intensive Cardiac Care Unit & Deputy Director, Division of Cardiology at Sheba MC sponsored by Neopharm
16:15-16:45	<u>Key note:</u> Implementation research: The state of current management of the heightened risk for ASCVD events in a cohort of patients with lupus erythematosus <i>Kevin Williams</i> , Cardiovascular Sciences, Professor of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, USA
17:30-19:00	Walking tour in Tel Aviv

Friday, 15/11/2024

08:00-08:25	Registration
08:25-08:30	Welcome
08:30-10:00	Session 4: IHS ISA joint session
Chairpersons	Alon Eisen & Barak Zafrir
08:30- 08:45	ESC hypertension guidelines, what is new? <i>Hadar Abramovitz, Rabin Medical Center</i>
08:50-09:05	Subclinical Atherosclerosis imaging – a key tool in primary prevention <i>Amir Aker, Carmel Medical Center</i>
09:10-09:25	LPa: Why is this important when there is no specific treatment? <i>Barak Zafrir, Carmel Medical Center</i>
09:30-10:00	Life time award to prof. Eran Leitersdorf. My journey in atherosclerosis
10:00-10:30	Coffee Break
10:30-10:45	Obesity diabetes GLP1 and atherosclerosis <i>Elena Izhakov, Tel-Aviv Sourasky Medical Center, Tel-Aviv</i>
10:50-11:25	Session 5: Treating Homozygote FH sponsored by Medison
10:50-11:05	Apheresis In HoFH <i>Eldad J Dann, Director of blood bank and Aphaeresis unit, RAMBAM medical care center and Technion Haifa</i>
11:10-11:25	Pharmacotherapy In HoFH <i>Cohen Hofit, Sheba Medical Center, Tel-Hashomer</i>
11:30-12:45	Session 6: Key aspects in atherosclerosis treatment sponsored by Sanofi
Chairpersons	Avishai Elis & Elena Izhakov
11:30-11:45	How to prevent the first CV event <i>Dov Gavish, Shaare Zedek Medical Center, Israel</i> sponsored by Sanofi
11:45-12:45	Challenging lipid cases (10 minutes each) TBA
13:00	Lunch